Drugs / Laroprovstat
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07622433 | Jun → Sep 2026 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07513571 | Apr → Jul 2026 overdue | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07316608 | Mar → Jun 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07423598 | Feb → Jun 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07216131 | Nov → Dec 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06742853 | Dec 2024 → Oct 2025 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06671405 | Sep 2024 → Feb 2025 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06576765 | Aug → Nov 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06592482 | Aug → Dec 2024 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05817461 | Apr → Jun 2023 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05787002 | Mar → May 2023 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07218900 | Nov 2025 → Sep 2026 expected | hyperlipidemia | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06692764 | Oct 2024 → Apr 2025 | atherosclerotic cardiovascular disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT06173570 | Jan → Sep 2024 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06834932 | Dec 2024 → Feb 2027 expected | hyperlipidemia | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07000136 | Jun 2025 → Jan 2027 expected | familial hypercholesterolemia | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07000357 | Jun 2025 → Oct 2029 expected | cardiovascular disorder | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07000123 | May 2025 → Jan 2027 expected | cardiovascular disorder | AstraZeneca | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05384262 Comparator | May 2022 → Jun 2024 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07619118 Comparator | Sep 2026 → May 2027 expected | hyperlipidemia | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07619131 Comparator | Aug 2026 → Jul 2027 expected | hyperlipidemia | AstraZeneca | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-31 | AstraZeneca | AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial astrazeneca.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Laroprovstat | “METHODS: Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain.” PMID 42137960 ↗ May 2026 |
| Known as | AZD0780 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216131 ↗ |
| Action | Inhibit | “Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia” PMID 42137960 ↗ May 2026 |
| Modality | Small molecule | “Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design” PMID 42137960 ↗ May 2026 |
| Route | Oral | “Subjects will receive AZD0780 orally as a multiple ascending dose.” NCT05384262 ↗ |
| Target | PCSK9 | “binds to the PCSK9 C-terminal domain” PMID 42137960 ↗ May 2026 |